Abstract
Vasopressin receptor antagonists (vaptans) are a new class of drugs to treat congestive heart failure. Since there are three subtypes of the receptor located in different tissues, it is important to devise tailor-made vaptans to target the appropriate receptor subtype. The binding of three vaptans, OPC21268, mozavaptan and tolvapatan was measured to the human V1-vascular vasopressin receptor (hV1R). Whereas arginine vasopressin (AVP) binds to hV1R and hV2R with equal affinity, vaptans interact differently with the receptor subtypes. The interaction of the three vaptans to the hV1R was probed by binding experiments to point mutants of residues postulated to line the binding pocket. The measurements suggest that the binding pocket on the hV1R is too small for tight binding of tolvaptan. The somewhat smaller mozavaptan is a slightly better binder to the hV1R. The data suggest ways to increase the affinity of tolvaptan to the hV1R by chemical modification.
Keywords: Antagonist, GPCR, Receptor, Mozavaptan, Tolvaptan, Vaptan, Vasopressin, arginine vasopressin (AVP), hV1R, vasodilation, hyponatremia, hypervolemia, V2R, adenylyl cyclase
Letters in Drug Design & Discovery
Title: Specificity of Three Vasopressin Receptor Antagonists
Volume: 8 Issue: 6
Author(s): Jeremy T. Saks, Barbara Truitt and Menachem Shoham
Affiliation:
Keywords: Antagonist, GPCR, Receptor, Mozavaptan, Tolvaptan, Vaptan, Vasopressin, arginine vasopressin (AVP), hV1R, vasodilation, hyponatremia, hypervolemia, V2R, adenylyl cyclase
Abstract: Vasopressin receptor antagonists (vaptans) are a new class of drugs to treat congestive heart failure. Since there are three subtypes of the receptor located in different tissues, it is important to devise tailor-made vaptans to target the appropriate receptor subtype. The binding of three vaptans, OPC21268, mozavaptan and tolvapatan was measured to the human V1-vascular vasopressin receptor (hV1R). Whereas arginine vasopressin (AVP) binds to hV1R and hV2R with equal affinity, vaptans interact differently with the receptor subtypes. The interaction of the three vaptans to the hV1R was probed by binding experiments to point mutants of residues postulated to line the binding pocket. The measurements suggest that the binding pocket on the hV1R is too small for tight binding of tolvaptan. The somewhat smaller mozavaptan is a slightly better binder to the hV1R. The data suggest ways to increase the affinity of tolvaptan to the hV1R by chemical modification.
Export Options
About this article
Cite this article as:
T. Saks Jeremy, Truitt Barbara and Shoham Menachem, Specificity of Three Vasopressin Receptor Antagonists, Letters in Drug Design & Discovery 2011; 8 (6) . https://dx.doi.org/10.2174/157018011795906794
DOI https://dx.doi.org/10.2174/157018011795906794 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Early Growth Response-1 (EGR-1) – A Key player in Myocardial Cell Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Lifestyle Changes among ACS Survivors in Arabian Gulf Countries (Gulf COAST Registry)
Current Vascular Pharmacology The Role of Anticoagulation in IPF
Current Respiratory Medicine Reviews Receptor-Based 3D-QSAR Study for Recognizing True Binding Mode of Mercaptoacyldipeptides at the Active Site of Neutral Endopeptidase
Medicinal Chemistry The Optimal Treatment of Severe Hypertension in Pregnancy: Update of the Role of Nicardipine
Current Pharmaceutical Biotechnology Hepatocyte Growth Factor (HGF), an Endogenous Pulmotrophic Regulator, for the Rescue of Acute and Chronic Lung Diseases
Current Signal Transduction Therapy A Comprehensive and Contemporary Review on Immunosuppression Therapy for Heart Transplantation
Current Pharmaceutical Design Salutary Properties of YC-1 in the Cardiovascular and Hematological Systems
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design ACE Inhibition Prevents Diastolic Ca2+ Overload and Loss of Myofilament Ca2+ Sensitivity after Myocardial Infarction
Current Molecular Medicine Biomarkers in Molecularly Targeted Therapy for Cancer
Recent Patents on Biomarkers Is there U-turn from Insulin Back to Pills in Diabetes?
Current Vascular Pharmacology Identification and Treatment of Patients with Early COPD
Current Respiratory Medicine Reviews Artificial Enzymes: A Review
Current Enzyme Inhibition Phase II and Pharmacological Study of Oral Docetaxel Plus Cyclosporin A in Anthracycline Pre-Treated Metastatic Breast Cancer
Current Clinical Pharmacology Tumor Necrosis Factor-α-Mediated Pulmonary Endothelial Barrier Dysfunction
Current Respiratory Medicine Reviews Antihistamines: Past Answers and Present Questions
Current Drug Safety Clinical Applications of Creatine Supplementation on Paediatrics
Current Pharmaceutical Biotechnology Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells
Mini-Reviews in Medicinal Chemistry